{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:16:44Z","timestamp":1786987004303,"version":"build-2736575974"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T00:00:00Z","timestamp":1748476800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Immunology"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.coi.2025.102585","type":"journal-article","created":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T09:50:07Z","timestamp":1749635407000},"page":"102585","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["A review of spatial transcriptomics in psoriasis: new insights into cellular contributions"],"prefix":"10.1016","volume":"95","author":[{"given":"Andrea","family":"Leung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgia","family":"Marquez-Grap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison","family":"Kranyak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7883-6439","authenticated-orcid":false,"given":"Wilson","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coi.2025.102585_bib1","series-title":"Medicom Conference Report Proceedings of the 7th IFPA WPPA Conference","article-title":"Advances in the genetics and immunology of psoriasis","author":"Leung","year":"2024"},{"key":"10.1016\/j.coi.2025.102585_bib2","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1126\/science.aaf2403","article-title":"Visualization and analysis of gene expression in tissue sections by spatial transcriptomics","volume":"353","author":"St\u00e5hl","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.coi.2025.102585_bib3","first-page":"483","article-title":"Genetic family history assessment","volume":"9","author":"Bender","year":"1998","journal-title":"AACN Clin Issue Adv Pract Acute Crit Care"},{"key":"10.1016\/j.coi.2025.102585_bib4","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1515\/cclm-2023-1245","article-title":"Skin in the game: a review of single-cell and spatial transcriptomics in dermatological research","volume":"62","author":"Schepps","year":"2024","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.coi.2025.102585_bib5","unstructured":"\u201cGet the Facts About Psoriasis and Psoriatic Arthritis.\u201d Accessed: Mar. 19, 2025. [Online]. Available: \u3008https:\/\/www.psoriasis.org\/psoriasis-statistics\u3009."},{"key":"10.1016\/j.coi.2025.102585_bib6","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1038\/s12276-020-00499-2","article-title":"Single-cell sequencing techniques from individual to multiomics analyses","volume":"52","author":"Kashima","year":"2020","journal-title":"Exp Mol Med"},{"key":"10.1016\/j.coi.2025.102585_bib7","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1080\/14712598.2022.2142465","article-title":"Biologic insights from single-cell studies of psoriasis and psoriatic arthritis","volume":"22","author":"Jin","year":"2022","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.coi.2025.102585_bib8","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/s41576-019-0093-7","article-title":"Integrative single-cell analysis","volume":"20","author":"Stuart","year":"2019","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.coi.2025.102585_bib9","doi-asserted-by":"crossref","DOI":"10.1126\/science.aba6500","article-title":"Developmental cell programs are co-opted in inflammatory skin disease","volume":"371","author":"Reynolds","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.coi.2025.102585_bib10","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.658984","article-title":"Stromal cells underlining the paths from autoimmunity, inflammation to cancer with roles beyond structural and nutritional support","author":"Honan","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.coi.2025.102585_sbref10","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2024.110283","article-title":"Tissue gene expression profiles and communication networks inform candidate blood biomarker identification in psoriasis and atopic dermatitis","volume":"265","author":"Soul","year":"2024","journal-title":"Clin Immunol"},{"key":"10.1016\/j.coi.2025.102585_sbref11","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-023-39484-4","article-title":"Differentiation of IL-26+ TH17 intermediates into IL-17A producers via epithelial crosstalk in psoriasis","volume":"14","author":"Fries","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.coi.2025.102585_sbref12","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/j.immuni.2024.04.022","article-title":"Metabolic coordination between skin epithelium and type 17 immunity sustains chronic skin inflammation","volume":"57","author":"Subudhi","year":"2024","journal-title":"Immunity"},{"key":"10.1016\/j.coi.2025.102585_bib14","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.7150\/thno.93764","article-title":"Energy competition remodels the metabolic glucose landscape of psoriatic epidermal cells","volume":"14","author":"Liu","year":"2024","journal-title":"Theranostics"},{"key":"10.1016\/j.coi.2025.102585_bib15","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1469829","article-title":"Sphingosine 1-phosphate receptor 2 in keratinocytes plays a key role in reducing inflammation in psoriasis","volume":"15","author":"Masuda-Kuroki","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.coi.2025.102585_bib16","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.jid.2024.09.010","article-title":"Profiling long noncoding RNA in Psoriatic skin using single-cell RNA sequencing","volume":"145","author":"Bogle","year":"2024","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.coi.2025.102585_sbref16","article-title":"Single cell and spatial sequencing define processes by which keratinocytes and fibroblasts amplify inflammatory responses in psoriasis","volume":"14","author":"Ma","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.coi.2025.102585_sbref17","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1093\/bjd\/ljae205","article-title":"Fibroblasts with high matrix metalloproteinase 2 expression regulate CD8+ T-cell residency and inflammation via CD100 in psoriasis","volume":"191","author":"Dong","year":"2024","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.coi.2025.102585_sbref18","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1093\/bjd\/ljae459","article-title":"Multitranscriptome analysis reveals stromal cells in the papillary dermis to promote angiogenesis in psoriasis vulgaris","volume":"192","author":"Zhang","year":"2025","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.coi.2025.102585_bib20","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-44346-6","article-title":"Integrated single-cell and spatial transcriptomics reveals heterogeneity of fibroblast and pivotal genes in psoriasis","volume":"13","author":"He","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.coi.2025.102585_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2023.109771","article-title":"Architecture of skin inflammation in psoriasis revealed by spatial transcriptomics","volume":"256","author":"Gniadecki","year":"2023","journal-title":"Clin Immunol"},{"key":"10.1016\/j.coi.2025.102585_bib22","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abq7991","article-title":"Spatial transcriptomics stratifies psoriatic disease severity by emergent cellular ecosystems","volume":"8","author":"Castillo","year":"2023","journal-title":"Sci Immunol"},{"key":"10.1016\/j.coi.2025.102585_sbref22","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1334844","article-title":"Spatial transcriptomics reveals altered lipid metabolism and inflammation-related gene expression of sebaceous glands in psoriasis and atopic dermatitis","volume":"15","author":"Seiringer","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.coi.2025.102585_sbref23","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.114513","article-title":"The mechano-chemical circuit in fibroblasts and dendritic cells drives basal cell proliferation in psoriasis","volume":"43","author":"Jiang","year":"2024","journal-title":"Cell Rep"},{"key":"10.1016\/j.coi.2025.102585_sbref24","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.jid.2024.07.006","article-title":"How can spatial transcriptomic profiling advance our understanding of skin diseases?","volume":"145","author":"Kumaran","year":"2025","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.coi.2025.102585_bib26","doi-asserted-by":"crossref","DOI":"10.1172\/JCI160451","article-title":"An IGFBP7hi endothelial cell subset drives T cell extravasation in psoriasis via endothelial glycocalyx degradation","volume":"133","author":"Li","year":"2023","journal-title":"J Clin Invest"},{"key":"10.1016\/j.coi.2025.102585_bib27","doi-asserted-by":"crossref","DOI":"10.3390\/cells9122627","article-title":"Skin-associated B cells in the pathogenesis of cutaneous autoimmune diseases-implications for therapeutic approaches","volume":"9","author":"Fetter","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.coi.2025.102585_bib28","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-81588-8","article-title":"Suppression of IL-23-mediated psoriasis-like inflammation by regulatory B cells","volume":"11","author":"Mizumaki","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.coi.2025.102585_bib29","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jdermsci.2015.11.003","article-title":"IL-10-producing regulatory B cells are decreased in patients with psoriasis","volume":"81","author":"Hayashi","year":"2016","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.coi.2025.102585_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.113388","article-title":"Current therapeutic overview and future perspectives regarding the treatment of psoriasis","volume":"143","author":"Ferrara","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.coi.2025.102585_bib31","doi-asserted-by":"crossref","DOI":"10.7573\/dic.2024-5-6","article-title":"New and emerging oral therapies for psoriasis","volume":"13","author":"Yilmaz","year":"2024","journal-title":"Drugs Context"},{"key":"10.1016\/j.coi.2025.102585_bib32","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1210\/er.2013-1053","article-title":"Clinical and molecular genetics of the phosphodiesterases (PDEs)","volume":"35","author":"Azevedo","year":"2014","journal-title":"Endocr Rev"},{"key":"10.1016\/j.coi.2025.102585_bib33","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2147\/PTT.S303634","article-title":"Phosphodiesterase-4 inhibition in psoriasis","volume":"11","author":"Milakovic","year":"2021","journal-title":"Psoriasis"},{"key":"10.1016\/j.coi.2025.102585_bib34","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.jaad.2023.11.005","article-title":"Orismilast in moderate-to-severe psoriasis: efficacy and safety from a 16-week, randomized, double-blinded, placebo-controlled, dose-finding, and phase 2b trial (IASOS)","volume":"90","author":"Warren","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.coi.2025.102585_bib35","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1111\/jdv.18818","article-title":"Pharmacology of orismilast, a potent and selective PDE4 inhibitor","volume":"37","author":"Silverberg","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.coi.2025.102585_bib36","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1007\/s13555-023-00977-1","article-title":"Matching-adjusted indirect comparison of the long-term efficacy of deucravacitinib versus adalimumab for moderate to severe plaque psoriasis","volume":"13","author":"Armstrong","year":"2023","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.coi.2025.102585_bib37","unstructured":"\u201cTakeda Announces Positive Results in Phase 2b Study of Investigational TAK-279, an Oral, Once-Daily TYK2 Inhibitor, in People with Moderate-to-Severe Plaque Psoriasis.\u201d Accessed: May 18, 2025. [Online]. Available: \u3008https:\/\/www.takeda.com\/newsroom\/newsreleases\/2023\/takeda-announces-positive-results-in-phase-2b-study-of-investigational-tak-279\/\u3009."},{"key":"10.1016\/j.coi.2025.102585_bib38","unstructured":"D.T. Inc\u00a0: \u201cDICE Therapeutics Announces Positive Topline Data from Phase 1 Clinical Trial of Lead Oral IL-17 Antagonist, DC-806, for Psoriasis\u201d; GlobeNewswire News Room. Accessed: May 18, 2025. [Online]. Available: \u3008https:\/\/www.globenewswire.com\/news-release\/2022\/10\/11\/2531642\/0\/en\/DICE-Therapeutics-Announces-Positive-Topline-Data-from-Phase-1-Clinical-Trial-of-Lead-Oral-IL-17-Antagonist-DC-806-for-Psoriasis.html\u3009."},{"key":"10.1016\/j.coi.2025.102585_bib39","unstructured":"DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company: \u201cA Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study to Evaluate the Efficacy and Safety of DC-806 in Participants With Moderate to Severe Plaque Psoriasis\u201d; clinicaltrials.gov, Clinical trial registration NCT05896527, Mar. 2025. Accessed: May 18, 2025. [Online]. Available: \u3008https:\/\/clinicaltrials.gov\/study\/NCT05896527\u3009."},{"key":"10.1016\/j.coi.2025.102585_bib40","unstructured":"Janssen Research & Development, LLC: \u201cA Phase 2b Multicenter, Randomized, Placebo Controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis\u201d; clinicaltrials.gov, Clinical trial registration NCT05223868, Apr. 2025. Accessed: May 18, 2025. [Online]. Available: \u3008https:\/\/clinicaltrials.gov\/study\/NCT05223868\u3009."},{"key":"10.1016\/j.coi.2025.102585_bib41","unstructured":"\u201cNew Data Shows JNJ-2113, the First and Only Investigational Targeted Oral Peptide, Maintained Skin Clearance in Moderate-to-Severe Plaque Psoriasis Through One Year\u201d; JNJ.com. Accessed: May 18, 2025. [Online]. Available: \u3008https:\/\/www.jnj.com\/media-center\/press-releases\/new-data-shows-jnj-2113-the-first-and-only-investigational-targeted-oral-peptide-maintained-skin-clearance-in-moderate-to-severe-plaque-psoriasis-through-one-year\u3009."},{"key":"10.1016\/j.coi.2025.102585_bib42","unstructured":"Janssen Research & Development, LLC: \u201cA Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Plaque Psoriasis Involving Special Areas\u201d;\u00a0clinicaltrials.gov, Clinical trial registration NCT06095102, Apr. 2025. Accessed: May 18, 2025. [Online]. Available: \u3008https:\/\/clinicaltrials.gov\/study\/NCT06095102\u3009."},{"key":"10.1016\/j.coi.2025.102585_bib43","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-13616-1","article-title":"Small molecules that inhibit TNF signalling by stabilising an asymmetric form of the trimer","volume":"10","author":"O\u2019Connell","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.coi.2025.102585_bib44","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.1037983","article-title":"An orally available small molecule that targets soluble TNF to deliver anti-TNF biologic-like efficacy in rheumatoid arthritis","volume":"13","author":"Vugler","year":"2022","journal-title":"Front Pharm"},{"key":"10.1016\/j.coi.2025.102585_bib45","unstructured":"\u201cThe Potential of an Oral TNF\u03b1 Inhibitor with TNFR1 Specificity: Results of a Phase 1b Proof-of-mechanism Trial in Psoriasis\u201d; ACR Meeting Abstracts. Accessed: May 18, 2025. [Online]. Available: \u3008https:\/\/acrabstracts.org\/abstract\/the-potential-of-an-oral-tnf\u03b1-inhibitor-with-tnfr1-specificity-results-of-a-phase-1b-proof-of-mechanism-trial-in-psoriasis\/\u3009."},{"key":"10.1016\/j.coi.2025.102585_bib46","unstructured":"Sanofi:\u00a0\u201cA Phase 2, International, Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study of Efficacy and Safety of SAR441566 in Adults With Moderate to Severe Plaque Psoriasis\u201d; clinicaltrials.gov, Clinical trial registration NCT06073119, Jan. 2025. Accessed: May 18, 2025. [Online]. Available: \u3008https:\/\/clinicaltrials.gov\/study\/NCT06073119\u3009."},{"key":"10.1016\/j.coi.2025.102585_bib47","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.759276","article-title":"Sphingosine-1-phosphate and its signal modulators alleviate psoriasis-like dermatitis: preclinical and clinical evidence and possible mechanisms","volume":"12","author":"Liu","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.coi.2025.102585_bib48","series-title":"Sun Pharma Announces Initiation of Phase 2 Clinical Trial of SCD-044 in Patients With Moderate to Severe Plaque Psoriasis","year":"2025"},{"key":"10.1016\/j.coi.2025.102585_bib49","unstructured":"Sun Pharmaceutical Industries Limited:\u00a0\u201cA Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy And Safety of SCD-044 in the Treatment of Moderate to Severe Plaque Psoriasis\u201d; clinicaltrials.gov, Clinical trial registration NCT04566666, Apr. 2025. Accessed: May 18, 2025. [Online]. Available: \u3008https:\/\/clinicaltrials.gov\/study\/NCT04566666\u3009."},{"key":"10.1016\/j.coi.2025.102585_bib50","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2147\/PTT.S294173","article-title":"Key Signaling pathways in psoriasis: recent insights from antipsoriatic therapeutics","volume":"11","author":"Ben Abdallah","year":"2021","journal-title":"Psoriasis"},{"key":"10.1016\/j.coi.2025.102585_bib51","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1468-3083.2011.04078.x","article-title":"Treatment of plaque-type psoriasis with oral CF101: data from an exploratory randomized phase 2 clinical trial","volume":"26","author":"David","year":"2012","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.coi.2025.102585_bib52","first-page":"931","article-title":"Treatment of plaque-type psoriasis with oral CF101: data from a phase II\/III multicenter, randomized, controlled trial","volume":"15","author":"David","year":"2016","journal-title":"J Drugs Dermatol"}],"container-title":["Current Opinion in Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952791525000615?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952791525000615?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T06:03:39Z","timestamp":1779084219000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0952791525000615"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":52,"alternative-id":["S0952791525000615"],"URL":"https:\/\/doi.org\/10.1016\/j.coi.2025.102585","relation":{},"ISSN":["0952-7915"],"issn-type":[{"value":"0952-7915","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A review of spatial transcriptomics in psoriasis: new insights into cellular contributions","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coi.2025.102585","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102585"}}